Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie is conducting a study titled A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects With CLL. The study aims to assess the safety of venetoclax when used with obinutuzumab or acalabrutinib in treating chronic lymphocytic leukemia (CLL), focusing on adverse events and changes in disease activity.
The study tests the combination of oral venetoclax with either intravenously infused obinutuzumab or oral acalabrutinib. Venetoclax is an oral tablet, while obinutuzumab is administered via intravenous infusion, and acalabrutinib is also an oral tablet. These combinations are intended to treat CLL more effectively.
This interventional study is randomized with a parallel intervention model, focusing on treatment without masking. It involves four treatment arms, each testing different combinations and ramp-up periods of the drugs.
The study began on August 5, 2024, with an estimated completion timeline of 28 months. The last update was submitted on June 30, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
For investors, this study could impact AbbVie’s stock performance, as successful results may enhance the company’s portfolio in the competitive CLL treatment market. It is essential to monitor updates as they may influence investor sentiment and market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.